Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. ×


Celiac.com Sponsor (A1):

Celiac.com Sponsor (A1-m):

  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.

    💬

    • Sign In
    • Sign Up
  • Jefferson Adams
    Jefferson Adams

    By Jefferson Adams •

    Are Serum Alkylresorcinols Good Biomarkers of Dietary Gluten Exposure in Celiacs?

    Followers 0
    Reviewed and edited by a celiac disease expert.

    A serum marker for gluten intake would help doctors tell if celiac patients are eating gluten-free.

    Are Serum Alkylresorcinols Good Biomarkers of Dietary Gluten Exposure in Celiacs? - Photo: CC--Garland Cannon
    Caption: Photo: CC--Garland Cannon

    Celiac.com 01/26/2017 - The only currently effective therapy for celiac disease is for patients to follow a gluten-free diet. However, no serum marker for gluten intake has yet been found, so it's not always easy for doctors to tell if patients are following their diets properly.

    A team of researchers recently set out to evaluate the use of alkylresorcinol concentrations for detecting dietary gluten intake in humans and mice.


    Celiac.com Sponsor (A12):




    Celiac.com Sponsor (A12-m):



    The research team included R. S. Choung, J. A. Murray, E. V. Marietta, C. T. Van Dyke, and A. B. Ross. They are variously affiliated with the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, and with the Department of Biology and Biological Engineering, Chalmers University of Technology in Gothenburg, Sweden.

    For their study, they compared alkylresorcinol concentrations among 34 treated patients with celiac disease, 36 untreated celiac disease patients and 33 control subjects. They also evaluated seven additional celiac disease patients whose serum samples were available at diagnosis and after gluten-free diet.

    In mice, they compared alkylresorcinol concentrations in the serum of five mice fed a regular chow, and 10 mice fed lifelong with a gluten-free chow. In addition, They also assessed the effect of added gluten on alkylresorcinol concentrations.

    Their study indicates that serum alkylresorcinol concentrations could be a useful marker for dietary gluten in celiac disease.

    Certainly, having an easy, reliable way for doctors to spot dietary gluten will be useful in helping people with celiac disease maintain their required gluten-free diets.

    Source:


    Followers 0
    Go to articles

    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.

    ×

  • Join eNewsletter

  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):



    Celiac.com Sponsors (A17-m):



  • Related Articles

    Jefferson Adams
    Celiac.com 07/04/2016 - The fast rising number of people diagnosed with celiac disease creates challenges to both the food industry and public officials to guarantee safe food.
    A great deal of effort is going into determining minimal celiac disease-eliciting doses of gluten and to refine and improve gluten-free labeling.
    A team of researchers recently set out to assess the harnessing of aptamers to overcome challenges in gluten detection. The research team included Rebeca Miranda-Castro, Noemí de-los-Santos-Álvarez, Arturo J. Miranda-Ordieres and María Jesús Lobo-Castañón of the Departamento de Química-Física y Analítica, Universidad de Oviedo in Oviedo, Spain.
    Their efforts rely largely on the ability to detect gluten protein in food samples at the lowest levels possible. Current analytical devices use antibodies to determine gluten protein levels. These devices have limited sensitivity, and also have some issues with the accuracy and reliability. Aptamers provide an ideal alternative for designing biosensors that can quickly and reliably measure gluten in foods.
    The team's article highlights the challenges in gluten detection, the current status of the use of aptamers for solving this problem, and what remains to be done to move these systems into commercial applications. They conclude: "The new receptors present high affinity and binding selectivity. In addition, they can be easily labeled with different reporter molecules at a relatively low production cost. These attributes make aptamers ideal reagents for the development of chemical sensors and analytical assays...Although still in its infancy, this sensitive technology will undoubtedly continue to advance."
    Source:
    Biosensors 2016, 6(2), 16; doi:10.3390/bios6020016
    Jefferson Adams
    Celiac.com 08/22/2016 - Many doctors hear from celiac patients who suffer from persistent symptoms despite a long-term gluten-free diet. A research team recently set out to investigate the prevalence and severity of these symptoms in patients with variable duration of a gluten-free diet.
    The research team included Pilvi Laurikka, Teea Salmi, Pekka Collin, Heini Huhtala, Markku Mäki, Katri Kaukinen, and Kalle Kurppa. They are variously affiliated with the School of Medicine, University of Tampere, Tampere 33014, Finland, the Department of Internal Medicine, the Department of Dermatology, the Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, University of Tampere, Tampere 33014, Finland, and the Tampere School of Health Sciences, at the University of Tampere in Tampere 33014, Finland, the Centre for Child Health Research at the University of Tampere and Tampere University Hospital, Tampere 33014, Finland.
    Altogether, the team classified 856 patients into three groups: 128 untreated patients, 93 on a short-term gluten-free diet of 1–2 years, and 635 patients on a long-term gluten-free diet of 3 years or longer. They conducted analyses of clinical and histological data and dietary adherence. They also included a control group of 166 healthy subjects.
    The team evaluated symptoms according to the validated GSRS questionnaire. They compared severity of symptoms against severity in cases of peptic ulcer, reflux disease, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
    Altogether, 93% of the short-term and 94% of the long-term treated patients had a strict gluten-free diet and recovered mucosa. Untreated patients had more diarrhea, indigestion and abdominal pain than those on a gluten-free diet and controls.
    Their results showed no differences in symptoms between the short- and long-term gluten-free diet groups, though both showed poorer GSRS total score than control subjects, with p = 0.03 and p = 0.05, respectively. Patients treated 1–2 years had more diarrhea (p = 0.03) and those treated >10 years had more cases of reflux (p = 0.04) than control subjects.
    Meanwhile, long-term treated celiac patients showed relatively mild symptoms compared with other gastrointestinal diseases.
    Based on these results, most celiac patients showed a good response to gluten-free diet, which continued in long-term follow-up, although not all patients see their health return to that of non-celiac individuals.
    Source:
    Nutrients 2016, 8(7), 429. doi:10.3390/nu8070429
    Jefferson Adams
    Celiac.com 11/23/2016 - Researchers know that kids with celiac disease have fully responded to a gluten-free diet when symptoms resolve and serology returns to normal.
    A team of researchers recently set out to assess the rate of normalization of the TTG and EMA for children on a gluten-free diet after diagnosis. The researchers included Dominica Gidrewicz, Cynthia L Trevenen, Martha Lyon, and J Decker Butzner.
    After initiated a gluten-free diet in 228 newly diagnosed children with biopsy-proven celiac disease, the team obtained and recorded celiac serologies over a 3.5 year period.
    The team categorized patients based on serology (Group A, TTG >= 10 x upper limit of normal (ULN) and EMA >= 1:80; Group B, TTG >= 10 x ULN and EMA and EMA <= 1:40; and Group C, TTG < 10 x ULN) and by severity of histologic injury at diagnosis.
    They found that in children in Group A showed the highest serology at diagnosis. Of those, 79.7% had abnormal TTG at 12 months after diagnosis (average TTG 12 mo, 68.8 +/- 7.3, normal < 20 kU/L).
    At two years, abnormal TTG persisted in 41.7% of Group A. By contrast, in Group C, which showed the lowest serology at diagnosis, only 35% of children displayed an abnormal TTG at 12 months (average TTG 14.3 +/- 1.9 kU/L). In kids with the most severe mucosal damage, Marsh 3C, 74.2% and 33.2% had an abnormal TTG at 1 and 2 year.
    The data in this study indicate that 3 out of 4 gluten-free diet compliant kids with the highest celiac serology or most severe mucosal injury at diagnosis, took longer than one year in for serology to return to normal.
    Doctors should take serology and histology into consideration at diagnosis in order to properly assess the patient's response to the gluten-free diet. That said, it's encouraging that even the more severe cases of celiac disease will eventually return to normal when the kids follow a gluten-free diet.
    Source:
    Journal of Pediatric Gastroenterology & Nutrition. doi: 10.1097/MPG.0000000000001270
    Jefferson Adams
    Celiac.com 12/08/2016 - People with celiac disease are supposed to follow a strict lifelong gluten-free diet. Celiac patients should receive regular follow-up dietary interviews and blood tests to make sure that they are successfully following the diet.
    However, none of these methods offer an accurate measure of dietary compliance. The only way to know for sure, is to test. A team of researchers recently set out to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of gluten-free diet adherence in celiac patients and compare it with traditional methods of gluten-free diet monitoring.
    The team conducted a prospective, nonrandomized, multi-center study including 188 celiac patients on gluten-free diet and 84 healthy controls. Subjects were given a dietary questionnaire and fecal GIP quantified by enzyme-linked immunosorbent assay (ELISA). They simultaneously measured serological anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies.
    A total of 56 of the 188 celiac patients, about 30 percent, had detectable GIP levels in stools. There was significant association between age and GIP in stools that revealed increasing dietary transgressions with advancing age. Nearly forty percent occurred in in subjects 13 years of age or older, with 60% occurring in men 13 years of age or older.
    The team found no connection between fecal GIP and dietary questionnaire or anti-tTG antibodies. However, they did spot a connection between GIP and anti-DGP antibodies, with seven of the 53 GIP stool-positive patients testing positive for anti-DGP.
    The detection of gluten peptides in stool samples shows the limits of traditional methods for monitoring a gluten-free diet in celiac patients. The GIP ELISA provides direct and quantitative assessment of gluten exposure soon after consumption, and might improve diagnosis and clinical management of non-responsive celiac disease and refractory celiac disease.
    Basically, doctors need to take a much more hands on role in monitoring celiac patients who are following gluten-free diets.
    Source:
    Am J Gastroenterol 2016; 111:1456–1465; doi:10.1038/ajg.2016.439; published online 20 September 2016 The research team included Isabel Comino PhD1, Fernando Fernández-Bañares MD, PhD2, María Esteve MD, PhD2, Luís Ortigosa MD, PhD3, Gemma Castillejo MD, PhD4, Blanca Fambuena MS5, Carmen Ribes-Koninckx MD, PhD6, Carlos Sierra MD, PhD7, Alfonso Rodríguez-Herrera MD, PhD8, José Carlos Salazar MD9, Ángel Caunedo MD10, J M Marugán-Miguelsanz MD, PhD11, José Antonio Garrote MD, PhD12, Santiago Vivas MD, PhD13, Oreste lo Iacono MD, PhD14, Alejandro Nuñez BSc13, Luis Vaquero MD, PhD13, Ana María Vegas MD12, Laura Crespo MD12, Luis Fernández-Salazar MD, PhD11, Eduardo Arranz MD, PhD11, Victoria Alejandra Jiménez-García MD10, Marco Antonio Montes-Cano MD, PhD15, Beatriz Espín MD, PhD9, Ana Galera MD8, Justo Valverde MD8, Francisco José Girón MD7, Miguel Bolonio MSc6, Antonio Millán MD, PhD5, Francesc Martínez Cerezo 4, César Guajardo MD3, José Ramón Alberto MD3, Mercé Rosinach MD, PhD2, Verónica Segura BSc1, Francisco León MD, PhD16, Jorge Marinich PhD17, Alba Muñoz-Suano PhD17, Manuel Romero-Gómez MD, PhD5, Ángel Cebolla PhD17 and Carolina Sousa PhD1
    They are variously affiliated with the Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain; the Department of Gastroenterology, Hospital Universitari Mutua Terrassa, and CIBERehd, Terrassa, Barcelona, Spain; the Pediatric Gastroenterology, Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Spain; Pediatric Gastroenterology, Hospital Universitari de Sant Joan de Reus, IISPV, URV, Reus, Spain; the Unit for the Clinical Management of Digestive Diseases and CIBERehd and Gastroenterology and Nutrition Unit, Hospital Universitario Virgen de Valme, Seville, Spain; the Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario y Politécnico La Fe, Celiac Disease and Digestive Inmunopatology Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; the Pediatric Gastroenterology and Nutrition Unit, Hospital Materno-Infantil, Malaga, Spain; the Gastroenterology and Nutrition Unit, Instituto Hispalense de Pediatría, Seville, Spain; the Servicio de Gastroenterología Pediátrica, Hospital Universitario Virgen del Rocío, Seville, Spain; the Hospital Universitario Virgen Macarena, Seville, Spain; the Mucosal Immunology Laboratory, Instituto de Biología y Genética Molecular (IBGM), University of Valladolid, CSIC and Gastroenterology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; the Clinical Analysis and Pediatrics, Hospital Universitario Río Hortega, Valladolid, Spain; the Servicio de Aparato Digestivo, Hospital Universitario de Leon, Leon, Spain; the Sección de Aparato Digestivo, Hospital del Tajo, Madrid, Spain; the Servicio de Inmunología, CIBER de Epidemiología y Salud Pública, Hospital Universitario Virgen del Rocío/IBiS/CSIC/Universidad de Sevilla, Seville, Spain; with Celimmune, Bethesda, Maryland, USA, and with Biomedal SL, Seville, Spain

  • Popular Now

HONcode Trustworthy Health Info Compliance

0_HONConduct789191_hr1.jpg

This site complies with the HONcode standard for trustworthy health information:
verify here.
View HONcode Certificate.

Navigation

About Celiac.com


Join eNewsletter

Popular Articles

Cookie Use

 

This site places cookies on your device (Cookie Settings). Continued use is acceptance of our Terms of Use, and Privacy Policy.     

×
×
  • Create New...